Advice
Following a resubmission.
Accepted for use within NHS Scotland.
The evidence of efficacy for Metvix for the treatment of thin or non-hyperkeratotic and nonpigmented actinic keratosis on the face and scalp is not strong. The health economic evidence is incomplete, though it suggests similar costs to the alternative treatment (cryotherapy). However, Metvix appears to have a place for treatment of those patients when other therapies are considered less appropriate and should be delivered by a dermatologist experienced in this therapy.
Download detailed advice18KB (PDF)
Medicine details
- Medicine name:
- Methyl aminolevulinate (Metvix cream®)
- SMC ID:
- 50/03
- Indication:
- Actinic keratoses
- Pharmaceutical company
- Galderma (UK) Ltd
- BNF chapter
- Skin
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 10 November 2003